Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy

Matthew R. Cooperberg, Shiro Hinotsu, Mikio Namiki, Kazuto Ito, Jeanette Broering, Peter R. Carroll, Hideyuki Akaza

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Purpose: Prostate cancer epidemiology has been marked overall by a downward risk migration over time. However, in some populations, both in the United States and abroad, many men are still diagnosed with high-risk and/or advanced disease. Primary androgen deprivation therapy (PADT) is frequently offered to these patients, and disease risk prediction is not well-established in this context. We compared risk features between large disease registries from the United States and Japan, and aimed to build and validate a risk prediction model applicable to PADT patients. Methods: Data were analyzed from 13,740 men in the United States community-based Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry and 19,265 men in the Japan Study Group of Prostate Cancer (J-CaP) database, a national Japanese registry of men receiving androgen deprivation therapy. Risk distribution was compared between the two datasets using three well-described multivariable instruments. A novel instrument (Japan Cancer of the Prostate Risk Assessment [J-CAPRA]) was designed and validated to be specifically applicable to PADT patients, and more relevant to high-risk patients than existing instruments. Results: J-CaP patients are more likely than CaPSURE patients to be diagnosed with high-risk features; 43% of J-CaP versus 5% of CaPSURE patients had locally advanced or metastatic disease that could not be stratified with the standard risk assessment tools. J-CAPRA-scored 0 to 12 based on Gleason score, prostate-specific antigen level, and clinical stage-predicts progression-free survival among PADT patients in J-CaP with a c-index of 0.71, and cancer-specific survival among PADT patients in CaPSURE with a c-index of 0.84. Conclusion: The novel J-CAPRA is the first risk instrument developed and validated for patients undergoing PADT. It is applicable to those with both localized and advanced disease, and performs well in diverse populations.

Original languageEnglish
Pages (from-to)4306-4313
Number of pages8
JournalJournal of Clinical Oncology
Volume27
Issue number26
DOIs
Publication statusPublished - Sep 10 2009
Externally publishedYes

Fingerprint

Androgens
Prostatic Neoplasms
Japan
Registries
Therapeutics
Research
Neoplasm Grading
Prostate-Specific Antigen
Population
Disease-Free Survival
Epidemiology
Databases
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Cooperberg, M. R., Hinotsu, S., Namiki, M., Ito, K., Broering, J., Carroll, P. R., & Akaza, H. (2009). Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. Journal of Clinical Oncology, 27(26), 4306-4313. https://doi.org/10.1200/JCO.2008.21.5228

Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. / Cooperberg, Matthew R.; Hinotsu, Shiro; Namiki, Mikio; Ito, Kazuto; Broering, Jeanette; Carroll, Peter R.; Akaza, Hideyuki.

In: Journal of Clinical Oncology, Vol. 27, No. 26, 10.09.2009, p. 4306-4313.

Research output: Contribution to journalArticle

Cooperberg, MR, Hinotsu, S, Namiki, M, Ito, K, Broering, J, Carroll, PR & Akaza, H 2009, 'Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy', Journal of Clinical Oncology, vol. 27, no. 26, pp. 4306-4313. https://doi.org/10.1200/JCO.2008.21.5228
Cooperberg, Matthew R. ; Hinotsu, Shiro ; Namiki, Mikio ; Ito, Kazuto ; Broering, Jeanette ; Carroll, Peter R. ; Akaza, Hideyuki. / Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 26. pp. 4306-4313.
@article{99526125cb8a4d2f8c3fa8149a1bdfdd,
title = "Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy",
abstract = "Purpose: Prostate cancer epidemiology has been marked overall by a downward risk migration over time. However, in some populations, both in the United States and abroad, many men are still diagnosed with high-risk and/or advanced disease. Primary androgen deprivation therapy (PADT) is frequently offered to these patients, and disease risk prediction is not well-established in this context. We compared risk features between large disease registries from the United States and Japan, and aimed to build and validate a risk prediction model applicable to PADT patients. Methods: Data were analyzed from 13,740 men in the United States community-based Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry and 19,265 men in the Japan Study Group of Prostate Cancer (J-CaP) database, a national Japanese registry of men receiving androgen deprivation therapy. Risk distribution was compared between the two datasets using three well-described multivariable instruments. A novel instrument (Japan Cancer of the Prostate Risk Assessment [J-CAPRA]) was designed and validated to be specifically applicable to PADT patients, and more relevant to high-risk patients than existing instruments. Results: J-CaP patients are more likely than CaPSURE patients to be diagnosed with high-risk features; 43{\%} of J-CaP versus 5{\%} of CaPSURE patients had locally advanced or metastatic disease that could not be stratified with the standard risk assessment tools. J-CAPRA-scored 0 to 12 based on Gleason score, prostate-specific antigen level, and clinical stage-predicts progression-free survival among PADT patients in J-CaP with a c-index of 0.71, and cancer-specific survival among PADT patients in CaPSURE with a c-index of 0.84. Conclusion: The novel J-CAPRA is the first risk instrument developed and validated for patients undergoing PADT. It is applicable to those with both localized and advanced disease, and performs well in diverse populations.",
author = "Cooperberg, {Matthew R.} and Shiro Hinotsu and Mikio Namiki and Kazuto Ito and Jeanette Broering and Carroll, {Peter R.} and Hideyuki Akaza",
year = "2009",
month = "9",
day = "10",
doi = "10.1200/JCO.2008.21.5228",
language = "English",
volume = "27",
pages = "4306--4313",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "26",

}

TY - JOUR

T1 - Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy

AU - Cooperberg, Matthew R.

AU - Hinotsu, Shiro

AU - Namiki, Mikio

AU - Ito, Kazuto

AU - Broering, Jeanette

AU - Carroll, Peter R.

AU - Akaza, Hideyuki

PY - 2009/9/10

Y1 - 2009/9/10

N2 - Purpose: Prostate cancer epidemiology has been marked overall by a downward risk migration over time. However, in some populations, both in the United States and abroad, many men are still diagnosed with high-risk and/or advanced disease. Primary androgen deprivation therapy (PADT) is frequently offered to these patients, and disease risk prediction is not well-established in this context. We compared risk features between large disease registries from the United States and Japan, and aimed to build and validate a risk prediction model applicable to PADT patients. Methods: Data were analyzed from 13,740 men in the United States community-based Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry and 19,265 men in the Japan Study Group of Prostate Cancer (J-CaP) database, a national Japanese registry of men receiving androgen deprivation therapy. Risk distribution was compared between the two datasets using three well-described multivariable instruments. A novel instrument (Japan Cancer of the Prostate Risk Assessment [J-CAPRA]) was designed and validated to be specifically applicable to PADT patients, and more relevant to high-risk patients than existing instruments. Results: J-CaP patients are more likely than CaPSURE patients to be diagnosed with high-risk features; 43% of J-CaP versus 5% of CaPSURE patients had locally advanced or metastatic disease that could not be stratified with the standard risk assessment tools. J-CAPRA-scored 0 to 12 based on Gleason score, prostate-specific antigen level, and clinical stage-predicts progression-free survival among PADT patients in J-CaP with a c-index of 0.71, and cancer-specific survival among PADT patients in CaPSURE with a c-index of 0.84. Conclusion: The novel J-CAPRA is the first risk instrument developed and validated for patients undergoing PADT. It is applicable to those with both localized and advanced disease, and performs well in diverse populations.

AB - Purpose: Prostate cancer epidemiology has been marked overall by a downward risk migration over time. However, in some populations, both in the United States and abroad, many men are still diagnosed with high-risk and/or advanced disease. Primary androgen deprivation therapy (PADT) is frequently offered to these patients, and disease risk prediction is not well-established in this context. We compared risk features between large disease registries from the United States and Japan, and aimed to build and validate a risk prediction model applicable to PADT patients. Methods: Data were analyzed from 13,740 men in the United States community-based Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry and 19,265 men in the Japan Study Group of Prostate Cancer (J-CaP) database, a national Japanese registry of men receiving androgen deprivation therapy. Risk distribution was compared between the two datasets using three well-described multivariable instruments. A novel instrument (Japan Cancer of the Prostate Risk Assessment [J-CAPRA]) was designed and validated to be specifically applicable to PADT patients, and more relevant to high-risk patients than existing instruments. Results: J-CaP patients are more likely than CaPSURE patients to be diagnosed with high-risk features; 43% of J-CaP versus 5% of CaPSURE patients had locally advanced or metastatic disease that could not be stratified with the standard risk assessment tools. J-CAPRA-scored 0 to 12 based on Gleason score, prostate-specific antigen level, and clinical stage-predicts progression-free survival among PADT patients in J-CaP with a c-index of 0.71, and cancer-specific survival among PADT patients in CaPSURE with a c-index of 0.84. Conclusion: The novel J-CAPRA is the first risk instrument developed and validated for patients undergoing PADT. It is applicable to those with both localized and advanced disease, and performs well in diverse populations.

UR - http://www.scopus.com/inward/record.url?scp=70349320376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349320376&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.21.5228

DO - 10.1200/JCO.2008.21.5228

M3 - Article

VL - 27

SP - 4306

EP - 4313

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 26

ER -